Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.

Abstract

PURPOSE:

This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer.

PATIENTS AND METHODS:

Women with histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer with measurable disease were enrolled between January 2015 and January 2018 in this open-label, four-arm, multicenter, phase II study. Patients received adavosertib (oral capsules, 2 days on/5 days off or 3 days on/4 days off) in six cohorts from 175 mg once daily to 225 mg twice daily combined with gemcitabine, paclitaxel, carboplatin, or pegylated liposomal doxorubicin. The primary outcome measurement was overall response rate.

RESULTS:

Three percent of patients (3/94) had confirmed complete response and 29% (27/94) had confirmed partial response. The response rate was highest with carboplatin plus weekly adavosertib, at 66.7%, with 100% disease control rate, and median progression-free survival of 12.0 months. The longest median duration of response was in the paclitaxel cohort (12.0 months). The most common grade ≥3 adverse events across all cohorts were neutropenia [45/94 (47.9%) patients], anemia [31/94 (33.0%)], thrombocytopenia [30/94 (31.9%)], and diarrhea and vomiting [10/94 (10.6%) each].

CONCLUSIONS:

Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.

• Authors: Kathleen N Moore, Setsuko K Chambers, Erika P Hamilton, Lee-May Chen, Amit M Oza, Sharad A Ghamande, Gottfried E Konecny, Steven C Plaxe, Daniel L Spitz, Jill J J Geenen, Tiffany A Troso-Sandoval, Janiel M Cragun, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Zhongwu Lai, Juliann Chmielecki, Suzanne F Jones, David R Spigel, Karen A Cadoo
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 28 Issue 1 Pg. 36-44 (01 01 2022) ISSN: 1557-3265 [Electronic] United States
• PMID: 34645648 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Comment)
• Copyright: ©2021 American Association for Cancer Research.

Chemical References

• Pyrazoles
• Pyrimidinones
• Platinum
• Carboplatin
• adavosertib
• Paclitaxel

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Carboplatin (adverse effects)
• Fallopian Tubes
• Female
• Humans
• Ovarian Neoplasms (drug therapy)
• Paclitaxel (adverse effects)
• Platinum (therapeutic use)
• Pyrazoles
• Pyrimidinones